Evidence map›Paper›PMID 12571644›Full record

ArticleGene therapy2003

Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.

E Vigne, J-F Dedieu, A Brie, A Gillardeaux, D Briot, K Benihoud, M Latta-Mahieu, P Saulnier, M Perricaudet, P Yeh

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.International journal of molecular sciences · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.Molecular therapy : the journal of the American Society of Gene Therapy · 2009
    Article
  9. Article
  10. Article
  11. Review
  12. Current developments in adenovirus-based cancer gene therapy.Future oncology (London, England) · 2006
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

E VigneUMR1582 CNRS/IGR/Aventis, Institut Gustave Roussy, Villejuif, France.
J-F Dedieu
A Brie
A Gillardeaux
D Briot
K Benihoud
M Latta-Mahieu
P Saulnier
M Perricaudet
P Yeh
Centre National de la Recherche Scientifique · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of genetically modified adenoviral vectors capable of specifically transducing a given cell population requires the addition and functional presentation of particular tropism determinants within the virus capsid, together with the abrogation of the molecular determinants that dictate their natural tropism in vivo. The human adenovirus serotype 5 (Ad5) first attaches to the cell surface following high-affinity binding of the C-terminal knob of the fiber capsid protein to the coxsackie and adenovirus receptor (CAR). Here we have assessed whether genetic shortening of the fiber shaft (virus BS1), or replacing the Ad5 fiber shaft and knob with their Ad3 counterparts (virus DB6), could cripple this interaction in vitro and in vivo. A 10-fold decrease in the binding of the modified capsids to soluble CAR was evidenced, which correlated with a similar reduction of their ability to transduce CAR-positive cells in vitro. The ability of BS1 to interact with cellular integrins was also impaired, suggesting that the penton base and the short-shafted fiber when embedded in the capsid preclude each other from efficiently interacting with their cognate cell surface receptors (CAR and integrins respectively). BS1 and DB6 intravenous injections in mice further supported a profound impairment of the ability of the capsid-modified viruses to transduce the liver as demonstrated by a 10-fold reduction of intracellular viral DNA and transgene expression. Interestingly enough, the host humoral response was also specifically weakened in BS1- and DB6-inoculated animals. Taken together, these observations indicate that (i) fiber shortening and (ii) pseudo-typing of Ad5-based vectors with the shaft and knob from non-CAR-binding serotypes constitute two promising strategies to successfully attenuate their native tropism in vitro and most importantly in vivo.

Indexed as

Eye ProteinsLipoproteinsNerve Tissue ProteinsAnimalsCalcium-Binding ProteinsCapsid ProteinsCell LineDNAGene ExpressionGene TargetingGenetic EngineeringGenetic TherapyGenetic VectorsHippocalcinLiverMiceCalcium-Binding ProteinsCapsid ProteinsDNAEye Proteinshexon capsid protein, AdenovirusHippocalcinLipoproteinsNerve Tissue ProteinsRcvrn protein, mouseRecoverin

Identifiers

PMID12571644
OpenAlexW1983055880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.